Austria · Delayed Price · Currency is EUR Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of EUR 124.03 billion. The enterprise value is 164.02 billion.
| Market Cap | 124.03B |
| Enterprise Value | 164.02B |
Important Dates
The last earnings date was Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Jan 23, 2026 |
Share Statistics
| Current Share Class | 5.69B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | -0.49% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 66.20% |
| Float | 5.68B |
Valuation Ratios
The trailing PE ratio is 18.74 and the forward PE ratio is 8.61.
| PE Ratio | 18.74 |
| Forward PE | 8.61 |
| PS Ratio | 2.33 |
| PB Ratio | 1.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 24.78 |
| EV / Sales | 3.10 |
| EV / EBITDA | 7.54 |
| EV / EBIT | 10.11 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 2.41 |
| Debt / FCF | n/a |
| Interest Coverage | 7.17 |
Financial Efficiency
Return on equity (ROE) is 8.58% and return on invested capital (ROIC) is 13.68%.
| Return on Equity (ROE) | 8.58% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.68% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 658,007 |
| Profits Per Employee | 81,711 |
| Employee Count | 81,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -226.55M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.31% |
| 50-Day Moving Average | 21.86 |
| 200-Day Moving Average | 21.25 |
| Relative Strength Index (RSI) | 51.64 |
| Average Volume (20 Days) | 809 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.12 |
Income Statement
In the last 12 months, Pfizer had revenue of EUR 53.30 billion and earned 6.62 billion in profits. Earnings per share was 1.16.
| Revenue | 53.30B |
| Gross Profit | 40.40B |
| Operating Income | 16.32B |
| Pretax Income | 6.41B |
| Net Income | 6.62B |
| EBITDA | 21.88B |
| EBIT | 16.32B |
| Earnings Per Share (EPS) | 1.16 |
Balance Sheet
The company has 12.76 billion in cash and 52.75 billion in debt, with a net cash position of -39.99 billion.
| Cash & Cash Equivalents | 12.76B |
| Total Debt | 52.75B |
| Net Cash | -39.99B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 79.29B |
| Book Value Per Share | 13.90 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 75.81%, with operating and profit margins of 30.62% and 12.42%.
| Gross Margin | 75.81% |
| Operating Margin | 30.62% |
| Pretax Margin | 12.02% |
| Profit Margin | 12.42% |
| EBITDA Margin | 41.05% |
| EBIT Margin | 30.62% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.49, which amounts to a dividend yield of 6.89%.
| Dividend Per Share | 1.49 |
| Dividend Yield | 6.89% |
| Dividend Growth (YoY) | -5.99% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | 6.66% |
| Earnings Yield | 5.34% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |